论文部分内容阅读
目的:研究氟桂嗪对蛛网膜下腔出血(SAH)血管痉挛(CVS)的预防和治疗作用。方法:对34例未用氟桂嗪组(对照组) 与38例用氟桂嗪预防组,和24例已发生CVS用氟桂嗪治疗组,于3～4周后分别进行经颅多普勒(TCD)及临床观察。结果:未用 氟桂嗪组脑血管血流速度明显加快,与预防组相比有显著差异(P<0.01),已发生CVS患者用药治疗后脑血管血流速度明显降 低,痉挛缓解(P<0.05)。结论:氟桂嗪预防和治疗SAH后CVS安全有效。
Objective: To study the preventive and therapeutic effects of flunarizine on vasospasm (CVS) in patients with subarachnoid hemorrhage (SAH). Methods: Thirty-four patients without flunarizine (control group) and 38 patients with flunarizine prevention group and 24 patients with CVS treated with flunarizine were treated with fluoxetine for 3 to 4 weeks, respectively. TCD and clinical observation. Results: Cerebrovascular blood flow velocity was significantly increased in the non-flunarizine group compared with that in the prevention group (P <0.01). Cerebrovascular blood flow velocity was significantly decreased and spasticity was relieved after CVS treatment (P <0.05) ). Conclusion: Flunarizine is safe and effective in prevention and treatment of CVS after SAH.